Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Relmada Therapeutics Announces Promotions

This article was originally published in Scrip

Executive Summary

Relmada Therapeutics, Inc. has promoted Richard M. Mangano to chief scientific officer and Lisa Nolan to the newly created role of chief business officer. Mangano has experience leading R&D programs and previously held positions in discovery and clinical research at Hoffmann-La Roche, Lederle Laboratories, Wyeth Research, where he was acting therapeutic area director for neuroscience; and Adolor Corp., where he was vice-president of clinical research and development. Previously, Nolan was chief business officer at Topigen Pharmaceuticals, prior to this she was vice-president of global business development and strategic marketing for Skyepharma PLC. Nolan also held various senior positions in business and marketing at West Pharmaceutical Services, Elan Corp., and Zeneca Pharmaceuticals. 

You may also be interested in...



Text Mining And Machine Reading: The Answer To Pharma's R&D Data Mountain?

How to make the most of the wealth of raw data in pharmaceutical R&D is an increasing challenge for the industry. The digital revolution is already having an impact in areas like clinical trials, and pharma is also starting to embrace new technologies in drug discovery.

Adherence Issues Add Weight To Digital Trials Push

Technology advancement has brought a wave of change in healthcare, with an increasing number of key pharma players now recognizing the potential of digital – particularly in clinical trials.

Appointments: Five Prime, Depomed, Gilead, Arix Bioscience and Corbus

This week's roundup includes high-level appointments by Five Prime Therapeutics, Depomed and Gilead Sciences and board appointments by Verseon, Arix Bioscience, and Corbus Pharmaceuticals.

Topics

Related Companies

UsernamePublicRestriction

Register

SC029968

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel